Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: Transgender and gender diverse (TGD) people have significantly higher rates of cardiovascular-related conditions than cisgender people, and Black and Hispanic people have higher rates of cardiovascular-related conditions than non-Hispanic White people. However, little is known about the prevalence of cardiovascular-related conditions among racial and ethnic subgroups of TGD people.

Objective: To compare the prevalence of cardiovascular-related conditions across racial and ethnic groups for TGD and cisgender people using quantitative intersectional methods.

Design, Setting, And Participants: Medicare enrollment and claims data were used from TGD and cisgender beneficiaries from 2011 to 2020. Using an established algorithm, likely TGD people were identified based on their diagnosis codes and care utilization. The 10 nearest-neighbor cisgender matches for each TGD beneficiary were identified based on propensity scores estimated from the original basis of eligibility, years of enrollment, age, and hospital service area.

Exposure: Race, ethnicity, and gender modality (TGD and cisgender). These data were analyzed from November 7, 2023, to October 31, 2024.

Main Outcomes And Measures: Rate of cardiovascular-related conditions (peripheral vascular disease, congestive heart failure, diabetes, hypertension, and chronic obstructive pulmonary disease) among Asian and Pacific Islander, Black, and Hispanic TGD beneficiaries compared with non-Hispanic White cisgender counterparts using generalized estimating equations, cardiovascular diseases and their risk factors. Attributable proportions for TGD Asian and Pacific Islander, Black, and Hispanic beneficiaries were calculated.

Results: Of the 36 004 TGD beneficiaries, 714 Asian and Pacific Islander (2%), 4518 Black (13%), and Hispanic 2545 (7%) had higher rates of cardiovascular-related conditions than 28 227 non-Hispanic White (78%) beneficiaries and higher than the 323 613 cisgender beneficiaries (5981 Asian and Pacific Islander [2%]; 40 781 Black [13%]; 22 417 Hispanic [7%]; 254 434 White [79%]). Black TGD beneficiaries had a 74% higher prevalence of peripheral vascular disease, 76% higher prevalence of congestive heart failure, and 50% higher prevalence of diabetes than similar non-Hispanic White cisgender beneficiaries. Overall, 6.3% of the excess peripheral vascular disease among Black TGD beneficiaries and 19.9% of the excess peripheral vascular disease among Asian and Pacific Islander TGD beneficiaries were associated with being at the intersection of gender, race, and ethnicity.

Conclusions And Relevance: This cross-sectional study found that Asian and Pacific Islander, Black, and Hispanic TGD beneficiaries had a high prevalence of cardiovascular-related conditions and had an elevated prevalence of several conditions, attributable to the intersection of gender, race, and ethnicity. Medicare should use the tools at its disposal to support the health of TGD beneficiaries.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374219PMC
http://dx.doi.org/10.1001/jamahealthforum.2025.3014DOI Listing

Publication Analysis

Top Keywords

cardiovascular-related conditions
28
tgd beneficiaries
28
asian pacific
24
pacific islander
24
black hispanic
16
non-hispanic white
16
peripheral vascular
16
vascular disease
16
tgd
15
higher rates
12

Similar Publications

Introduction: Nitides™ (Alvimedica, Istanbul, Turkey) is a novel polymer-free stent, which elutes Amphilimus™; a combination of sirolimus and long chain fatty acids. Aim of this prospective single-center study is to assess the efficacy and 12-months outcomes of patients with femoropopliteal arterial disease, who underwent successful angioplasty with implantation of Amphilimus™-eluting stents Nitides™.

Methods: Patients with peripheral arterial disease who underwent angioplasty of the femoropopliteal segment with DES Nitides™ from August 2021 to February 2024 were included in the study.

View Article and Find Full Text PDF

Background: Despite advances in treatment and the potential role of serum albumin as a prognostic biomarker, the mortality rate of individuals with coronary heart disease (CHD) continues to increase. Thus, this study aimed to assess the relationship between serum albumin levels and the risk of all-cause mortality and cardiovascular death in individuals with CHD.

Methods: This large-scale retrospective cohort study included 1556 participants diagnosed with CHD from the National Health and Nutrition Examination Survey spanning 1999 to 2015.

View Article and Find Full Text PDF

Aims: In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real-world settings.

Materials And Methods: Individuals initiating semaglutide 2.

View Article and Find Full Text PDF

Objectives: Coronary artery bypass grafting (CABG) using bilateral internal thoracic artery (BITA) conduits can achieve good outcomes for multivessel lesions. This study evaluated early angiographic patency and outcomes following off-pump CABG (OPCAB) using only in situ BITA and right gastroepiploic artery (rGEA) grafts.

Methods: This retrospective analysis included patients undergoing OPCAB using only in situ skeletonized BITA and rGEA grafts (July 2007 to March 2019).

View Article and Find Full Text PDF

A Nationwide Study of the Economic Burden of Obstructive Hypertrophic Cardiomyopathy in France.

Eur Heart J Qual Care Clin Outcomes

September 2025

Institut du Thorax, Centre Hospitalo-Universitaire Nantes, Nantes Université, CNRS, INSERM, Nantes, France.

Background: This study describes economic burden of obstructive hypertrophic cardiomyopathy in France, with consideration of disease severity as measured by New York Heart Association (NYHA) class.

Methods: This observational, retrospective study used data from the French National Health Data System. Adults (≥18) with at least one disease related hospitalization during 2012-2018 were included.

View Article and Find Full Text PDF